| Document |
Document Title |
|
JP2024512553A |
The present invention provides formula (I): The present invention relates to soluble epoxide hydrolase (sEH) inhibitors, methods for obtaining the same and therapeutic indications thereof.
|
|
JP7448474B2 |
It is provided a duplex stainless steel for use in a urea production plant and/or in a urea production process, containing in weight percentage (%w): C 0,03 or less; Si 0,5 or less; Mn 2,5 or less; Cr from more than 30,0 to 35,0; Ni from...
|
|
JP2024031085A |
The present invention provides a novel method for producing urea. [Solution] A first step of depolymerizing the carbonate resin by ammonolysis by bringing the carbonate resin into contact with ammonia, and a second step of recovering ure...
|
|
JP2024028840A |
The present invention provides compositions for treating cancer-producing PSMA by combining one or more radiotherapeutic agents with one or more shielding agents. A composition for treating cancer, the composition comprising a therapeuti...
|
|
JP7443364B2 |
Organic isocyanates are converted to ureas by heating in the presence of certain cobalt, magnesium, chromium and lanthanide series organometallic catalysts. The process requires no water or other reactants. The process is particularly us...
|
|
JP7442828B2 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I)to processes for their obtention and to their therapeutic indications.
|
|
JP2024028458A |
The present invention provides a modulator of the prostacyclin (PGI2) receptor useful for treating disorders associated with the PGI2 receptor. The compounds of the present invention and their pharmaceutical compositions are useful for: ...
|
|
JP2024508347A |
This disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials, and methods of using them. [Selection diagram] None
|
|
JP2024023324A |
The present invention provides compounds, compositions, and methods that are useful for modulating the integrated stress response (ISR) and treating related diseases; disorders and conditions. The invention features compounds, compositio...
|
|
JP7432214B2 |
[Problem] To provide a urea production device and a urea production method with which it is possible to produce urea under conditions which do not require a high temperature or high pressure, and using carbon dioxide and ammonia as start...
|
|
JP2024022507A |
[Problems] A method for synthesizing urea that can be synthesized under conditions of lower temperature and lower pressure, a method for producing silica particles that can be suitably used in the method for synthesizing urea, and a meth...
|
|
JP2024506253A |
Compounds of formula (I) in which the substituents are as defined in claim 1, as well as agrochemically acceptable salts, stereoisomers, enantiomers, tautomers of these compounds The N-oxide and the N-oxide can be used as insecticides.
|
|
JP2024017334A |
The present invention provides an extractant that selectively extracts at least one of a divalent cobalt salt and a divalent nickel salt. [Solution] A metal salt extractant is represented by the following general formula (1) and extracts...
|
|
JP7429688B2 |
The present disclosure relates to compounds useful as shielding agents for PSMA therapies. The present disclosure relates to methods of treating PSMA expressing cancers with one or more radiotherapeutics agents in combination with one or...
|
|
JP2024505327A |
This disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials, and methods of using them. [Selection diagram] None
|
|
JP2024015035A |
The present invention provides compounds, methods, and compositions that rapidly proliferate, maintain, and increase hematopoietic stem cells and/or hematopoietic progenitor cells derived from one or more sources of CD34+ cells. In parti...
|
|
JP7410337B2 |
The disclosure pertains to a urea production plant and process using a thermal stripper, wherein the reaction mixture is separated in two parts, wherein the first part is supplied at least in part to the thermal stripper and the second p...
|
|
JP7406236B2 |
To provide a method of generating urea from carbon dioxide and ammonia under low pressure.In one aspect, with ammonia dissolved in the high polarity solvent as the substrate, and an organic strong base as a catalyst, urea is generated. B...
|
|
JP7032323B6 |
The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPR1 a...
|
|
JP7397865B2 |
Monoisocyanate impurities are removed from a process stream obtained when solvent is separated from a polyisocyanate product. The monoisocyanates are reacted with amine compounds at specific molar ratios to produce ureas. The ureas can b...
|
|
JP2023550412A |
The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligan...
|
|
JP7389786B2 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
JP7382250B2 |
To provide a curable composition which enables formation of a cured coated film (cured product) having such elongation as to prevent a trouble in film molding, and satisfactorily progresses curing reaction, and a molding film which is br...
|
|
JP2023164798A |
To provide novel lipids and compositions involving the same.Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further includin...
|
|
JP2023164361A |
To provide: ionizable lipid compounds or pharmaceutically acceptable salts, isotopic variants, tautomers or stereoisomers thereof; nanoparticle pharmaceutical compositions comprising the compounds; and application of the compounds and th...
|
|
JP7370520B2 |
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...
|
|
JP7366002B2 |
The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
|
|
JP7364841B2 |
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...
|
|
JP2023541942A |
Reverse flow reactor (or another reactor with flow in opposite directions (or counterflow) during various parts of the process cycle) as part of a reaction system for producing ammonia and/or urea Provided are systems and methods for usi...
|
|
JP2023541422A |
Synthetic αvβ6 integrin ligands of formula I are described that have serum stability and affinity for integrin αvβ6, a receptor expressed on a variety of cell types. The described ligands are useful for delivering cargo molecules, su...
|
|
JP7353163B2 |
An ammonia derivative production plant includes: an electrolyzer for electrolyzing water; an ammonia synthesis system for synthesizing ammonia from hydrogen produced by the electrolyzer and nitrogen; a carbon dioxide generation system fo...
|
|
JP7337790B2 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
JP2023535926A |
The present invention provides 5-HT2AIt relates to novel compounds as receptor inhibitors or inverse agonists, processes for their preparation and pharmaceutical compositions thereof. The present invention also provides 5-HT2AIt relates ...
|
|
JP2023113615A |
To provide a novel compound that is useful in the treatment of diseases associated with TEAD transcription factor activity.The problem is solved by a compound of formula (I), or a pharmaceutically acceptable salt thereof. [L1 is absent o...
|
|
JP7326395B2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
JP2023111315A |
To provide a novel urea production method that is performed at low cost and environmentally friendly.A method for producing urea includes causing a reaction to occur among carbon monoxide, ammonia, and sulfur in water, preferably with a ...
|
|
JP2023108791A |
To provide an urea synthesis method capable of reducing energy and running cost necessary for synthesis of urea.In an urea synthesis method characterized by contacting an urea synthesis liquid generated in an urea synthesis tower A with ...
|
|
JP7317505B2 |
or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.
|
|
JP2023532047A |
The present disclosure provides formula I: Methods, pharmaceutical compositions, and kits are provided comprising a histone deacetylase (HDAC) inhibitor of, or a pharmaceutically acceptable salt thereof, wherein R1, R2, L1, L2, m, n, p, ...
|
|
JP2023103205A |
To provide compounds, compositions, medicaments and methods related to treatment of cancers expressing PSMA.For example, compounds of formula (I) or pharmaceutically acceptable salts thereof are presented.SELECTED DRAWING: Figure 7A
|
|
JP7313726B2 |
The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composi...
|
|
JP2023102640A |
To provide a novel technique related to a method for producing an urea compound.A method for producing an urea compound represented by a following general formula (5) includes a step (a) of bringing a composition comprising an amine comp...
|
|
JP2023531500A |
The present invention1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5and R6are as described herein; their preparation, their pharmaceutically acceptable salts, pharmaceutical compositions containing one or more compounds of formula (I), and t...
|
|
JP2023101031A |
To provide a method for producing O-methylisourea sulfate, which is important as an intermediate for pharmaceuticals, agricultural chemicals, and industrial chemicals, by a simple operation.Provided is a method for producing O-methylisou...
|
|
JP7311715B2 |
A urea production process which includes and a synthesis section, a recovery section and evaporation section and a finishing section wherein the evaporation section includes a first evaporator and downstream thereof a second evaporator f...
|
|
JP2023100758A |
To provide a carbamoyl phenylalaninol analog, and a method using the same material for treating the fault.A compound of formula I or a pharmaceutically acceptable salt thereof is provided. (Wherein, X is CH2, O, NH, S; Y is C=O, C=S, SO2...
|
|
JP2023529522A |
Provided herein are neutral lipids, cholesterol, and lipid nanoparticles to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Lipid...
|
|
JP7296948B2 |
The present disclosure provides a benzene fused heterocyclic derivative of Formula (I): is a single or double bond; n is an integer of 0 or 1; A is —CH2—, —CH(OH)—, or —C(O)—; G is C or N; X is —CH2—, O, or —C(O)—; Y ...
|
|
JP7296015B2 |
A urea production process comprising concentrating a first urea solution in a first vacuum evaporator in an evaporation section to give a urea melt and a first vapor, and condensing the first vapor in a first condensation section, wherei...
|
|
JP2023525767A |
The present disclosure provides methods and apparatus for scale-up production of lomustine via continuous-flow manufacturing. Such continuous flow processes may optionally include crystallization of lomustine and the apparatus may option...
|
